Organization | Jiangxi Children's Hospital

Jiangxi Children's Hospital Report issue

Academic/Hospital Phase 3 Phase 4

Founded: Nanchang China (1955)

Organization Overview

First Clinical Trial

2010

NCT01554930

First Marketed Drug

None

First NDA Approval

None

Last Known Activity

2016

Timeline

NOW

Now

Alternative names

Jiangxi Proincial Children's Hospital | Jiangxi Province Children's Hospital

Active Ingredients

Drugs in Phase 4 Trials (2)

sargramostim (leukine) (1 trial)

somatropin (protropin) (2 trials)

Drugs in Phase 3 Trials (6)

cladribine (leustatin) (1 trial)

cytarabine (cytosar-u) (1 trial)

filgrastim (neupogen) (1 trial)

idarubicin (idamycin) (1 trial)

mitoxantrone (novantrone) (1 trial)

sorafenib (nexavar) (1 trial)

Drugs in Other Trials (11)

betamethasone (celestone) (1 trial)

cyclophosphamide (cytoxan) (1 trial)

dipyridamole (persantine) (1 trial)

febrifuge (1 trial)

immune globulin (human) (1 trial)

lactulose (cephulac) (1 trial)

mannitol (1 trial)

methylprednisolone (medrol) (1 trial)

mycophenolate (myfortic) (1 trial)

paraffin oil (1 trial)

xiyanping (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)

Gonadal Dysgenesis (Phase 2)

Hepatoblastoma (Phase 4)

Leukemia (Phase 4)

Leukemia, Lymphoid (Phase 4)

Neuroblastoma (Phase 4)

Precursor Cell Lymphoblastic Leukemia-Lymphoma (Phase 4)

Retinoblastoma (Phase 4)

Syndrome (Phase 2)

Turner Syndrome (Phase 2)

Overview

Highest Phase: Phase 4
# of Trials: 7
# of Trial APIs: 19